Company intelligence / Profile preview

EmoLED

Ownership: Private
Development stage: Commercial

Overview

Clinical experience with the EmoLED blue light photobiomodulation device has demonstrated effectiveness in reducing healing time, inflammation, and pain for chronic wounds. The therapy is well tolerated and safe when used as directed by specialized personnel. There are no restrictions on lesion type except for neoplastic lesions.

The company also participates in advanced research collaborations such as the HyperProbe consortium to develop new imaging systems for neurosurgery.

Therapeutic areas: OncologyDermatology
Modalities: DeviceNon-pharmacological therapyPhotobiomodulation therapy (Blue LED light)
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

EmoLED

Commercial

Indications: Skin lesions, Wound healing

Partnerships

HyperProbe consortium—collaboration to develop hyperspectral imaging systems for neurosurgery funded by EU Horizon Europe program

Beyond the preview

Go deeper on EmoLED.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EmoLED.

Explore the full profile